Genmab slides as 'disappointing' 2026 outlook outweighs Q4 results

Genmab A/S

18/02/2026 08:35

** Shares in Denmark-based drugmaker Genmab GMAB.CO fall 4.6% after company reported Q4 results and "dissapointing" 2026 outlook as per Jyske Bank

** Genmab expects 2026 revenue in rage of USD 4,065-4,395 million and operating profit in rage of USD 900-1,400 million

** TD Cowen highlights that the guidance for both metrics appears soft when compared to market consensus estimates

** The report offered no significant pipeline news, with investor focus remaining on the three core products Epkinly, Rina-S, and Peto, despite management's confidence, says Jyske analysts

 (Reporting by Agnieszka Olenska)

 ((Agnieszka.Olenska@thomsonreuters.com;))